Post Authorisation Safety Study With Raxone in LHON Patients
NCT ID: NCT02771379
Last Updated: 2021-07-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
229 participants
OBSERVATIONAL
2016-09-30
2021-04-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
No medication will be provided as part of this study. Raxone® will be obtained through commercial channels.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study of Gene Therapy for The Treatment of Acute LHON Onset Within Three Months
NCT03428178
Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]
NCT02300753
Trial of Cyclosporine in the Acute Phase of Leber Hereditary Optic Neuropathy
NCT02176733
Extension Study Evaluating The Safety And Tolerability of AMX0035
NCT05619783
Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations
NCT02042326
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients who are treated with Raxone®
Idebenone
Raxone 900mg/day as per Raxone SmPC and medical judgement of treating physician.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Idebenone
Raxone 900mg/day as per Raxone SmPC and medical judgement of treating physician.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has completed an Informed Consent Form (ICF) indicating that he/she (or a legally acceptable representative) has been informed of all pertinent aspects of the study and has agreed to participate in the study;
* Patient is not participating in any interventional study.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Santhera Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitaetsklinikum Graz
Graz, , Austria
Medical University of Vienna
Vienna, , Austria
CHU de Nîmes - Hôpital Carémeau
Nîmes, Gard, France
CHU Angers - Hôpital Hôtel Dieu
Angers, Maine Et Loire, France
Hopital Roger Salengro - CHU Lille
Lille, Nord, France
Hôpital Européen Georges Pompidou
Paris, Paris Cedex 15, France
CHU Amiens - Centre Saint Victor
Amiens, Somme, France
Hospices Civils de Lyon
Lyon, , France
Hopital Neurologique Pierre Wertheimer
Lyon, , France
Centre Hospitalier National d'Ophtalmologie (CHNO) des Quinze-Vingts
Paris, , France
Fondation Ophtalmologique Adolphe de Rothschild
Paris, , France
Julius Maximilians University
Würzburg, Bavaria, Germany
Universitaetsklinikum Essen
Essen, , Germany
Universitaetsklinikum Freiburg
Freiburg im Breisgau, , Germany
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, , Germany
Universitaetsklinikum Heidelberg
Heidelberg, , Germany
Friedrich-Baur-Institut
Munich, , Germany
Universitaetsklinikum Muenster
Münster, , Germany
Dietrich-Bonhoeffer-Klinikum Neubrandenburg
Neubrandenburg, , Germany
Universitaetsklinikum Regensburg
Regensburg, , Germany
Athens Ophthalmological Center
Athens, , Greece
Università di Bologna-Clinica Neurologica-Dipartimento di Scienze Neurologiche
Bologna, , Italy
Ospedale San Raffaele
Milan, , Italy
Azienda Ospedaliera S. Camillo Forlanini
Rome, , Italy
Universitair Medisch Centrum Groningen
Groningen, , Netherlands
Maastricht University Medical Center
Maastricht, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SNT-IV-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.